Monocytes with Oncogenic Mutation  JAK2 V617F  as a Tool for Studies of the Pathogenic Mechanisms of Myelofibrosis

A. A. Silyutina; I. I. Gin; S. S. Prikhod’ko; S. V. Zhuk; P. A. Butylin; A. Yu. Zaritskii

doi:10.1007/s10517-018-4033-x

Monocytes with Oncogenic Mutation JAK2 V617F as a Tool for Studies of the Pathogenic Mechanisms of Myelofibrosis

Authors: Silyutina A.A.¹, Gin I.I.¹, Prikhod’ko S.S.¹, Zhuk S.V.¹, Butylin P.A.¹, Zaritskii A.Y.¹
Affiliations:
1. Research Laboratory of Oncohematology, Institute of Hematology, V. A. Almazov National Medical Research Centre
Issue: Vol 164, No 4 (2018)
Pages: 569-575
Section: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
URL: https://journals.rcsi.science/0007-4888/article/view/239750
DOI: https://doi.org/10.1007/s10517-018-4033-x
ID: 239750

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

We analyzed previously generated stable monocyte-derived cell line carrying mutation JAK2 V617F. Evaluation of the expression of pro- and antifibrotic factors revealed changes in the production of MMPs and their inhibitors, growth factors, galectin-3, and pentraxin 3 in cells carrying mutation JAK2 in comparison with control non-modified cells.